JOHN RENEAU

๐Ÿ‡บ๐Ÿ‡ธUnited States
Ownership
-
Employees
-
Market Cap
-
Website

Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia

Phase 2
Recruiting
Conditions
Interventions
First Posted Date
2022-10-24
Last Posted Date
2024-10-29
Lead Sponsor
Jonathan Brammer
Target Recruit Count
28
Registration Number
NCT05592015
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Memorial Sloan Kettering Cancer Center, New York, New York, United States

๐Ÿ‡บ๐Ÿ‡ธ

Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Oral Azacitidine for the Treatment of Relapsed or Refractory T-cell Large Granular Lymphocytic Leukemia

First Posted Date
2021-12-02
Last Posted Date
2024-10-29
Lead Sponsor
Jonathan Brammer
Target Recruit Count
27
Registration Number
NCT05141682
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

ยฉ Copyright 2024. All Rights Reserved by MedPath